Targeting neuronal nitric oxide synthase by a cell penetrating peptide Tat-LK15/siRNA bioconjugate (2017)
Sequence: RKKRRQRRRGGGKLLKLLLKLLLKLLK
| Experiment Id | EXP002075 |
|---|---|
| Paper | Targeting neuronal nitric oxide synthase by a cell penetrating peptide Tat-LK15/siRNA bioconjugate |
| Peptide | Tat-LK15 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | ~1.33 µg/mL Tat-LK15 (at 50 nM siRNA and 2:1 w/w) |
| Rna Concentration | 50 nM |
| Mixing Ratio | 2:1 (peptide/siRNA, w/w) |
| Formulation Format | CPP/siRNA electrostatic complex |
| Formulation Components | Tat-LK15 peptide + siRNA in HEPES-buffered saline (10 mM HEPES, pH 7.4) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | RGC-5 (rat retinal ganglion) cells; primary Rat Neurons–dorsal spinal cord (RNdsc) |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing (nNOS) in neuronal cells (WB + qPCR) |
| Output Value | ~58.5% decrease in nNOS protein; ~63.1% decrease in nNOS mRNA (vs model control) |
| Output Units | |
| Output Notes | RGC-5 cells with induced nNOS (oxygen-glucose deprivation + 145 mM NaCl). Tat-LK15/siRNA complex prepared at 2:1 w/w, incubated 30 min; uptake shown by FACS/immunofluorescence using FAM-siRNA; compared to Lipofectamine RNAiMAX (no significant difference). |
| Toxicity Notes | Low toxicity in RGC-5: apoptosis not significantly increased up to 5 µg/mL; mild increase at 10 µg/mL. Transfection condition (~1.33 µg/mL) within non-toxic range. |
| Curation Notes |